129 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
of lease liability
Total current liabilities
Long-term liabilities:
Royalty obligation payable to Iowa Economic Development Authority
Lease liability
Total
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
-term extension Long-term extension study for OraGrowtH Trials: Ongoing enrollment of patients from Phase 2 trials PK/PD trial Phase 2 Topline Data … 2 Phase 3 Status LUM-201 (Ibutamoren) in Moderate PGHD* Dose-finding trial Phase 2 Topline Data: Primary and secondary endpoints met (Nov 2023) Long
8-K
EX-99.1
eewzxxs1nvmqjn
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.1
jfikf
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
to3tcvzysv8sb3oi6ha
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.1
abg9zshaa8in 4a2
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.1
dusseygk24 asq0cs
14 Nov 22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
7:29am
8-K
EX-99.2
i2097 2eqz6r19bo6vvv
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.1
sh0t1832qop6a9o
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.2
3vtzl4vu0jcxv7t
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.1
2bugtum64 pgb
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm